Marshall Wace
CODX

Marshall Wace’s Co-Diagnostics CODX Stock Holding History

Marshall Wace’s Portfolio CODX Stock Details CODX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-7,376
Closed -$2.15M – 3915
2021
Q3 		$2.15M Buy
7,376
+6,197
+526% +$1.81M 0.01% 1490
2021
Q2 		$292K Buy
+1,179
New +$303K ﹤0.01% 2331

Other funds holding CODX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
ARC
Advisor Resource Council Dallas, Texas $309M AUM 22.32% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Marshall Wace's CODX Position: Q4 2021 in Review

Marshall Wace sold out of Co-Diagnostics (CODX) in Q4 2021, closing a stake of 7,376 shares — an estimated $2.15M sold.

Marshall Wace first reported a position in CODX in Q2 2021 and held it in 2 quarters. The position peaked at $2.15M in Q3 2021. 77 funds tracked by Wall St. Rank hold CODX as of Q4 2021.

  • Marshall Wace reported no remaining Co-Diagnostics position as of Q4 2021 after selling out during the quarter.
  • Marshall Wace sold 7,376 Co-Diagnostics shares in Q4 2021, an estimated $2.15M.
  • Marshall Wace first reported a position in Co-Diagnostics in Q2 2021 and held it in 2 quarters.
  • Marshall Wace's Co-Diagnostics position peaked at $2.15M in Q3 2021.
  • 77 funds tracked by Wall St. Rank held Co-Diagnostics as of Q4 2021.

Based on Marshall Wace's 13F filing for Q4 2021, filed 14 Feb 2022.